A Pipeline of Breakthrough Cancer Therapeutics
VAL-083 is a first-in-class small molecule DNA-targeting agent that exhibits a novel mechanism of action that results in DNA double strand breaks and cancer cell death. Published pre-clinical and clinical data suggest that VAL-083 may be active against a range of tumor types.
VAL-083's indications include:
- Glioblastoma Multiforme (GBM)
- Ovarian Cancer
- Pediatric CNS Tumors
REM-001 is a second generation photosensitizer drug possessing multiple advantages over earlier generation PDT compounds.
REM-001’s indications include:
- Cutaneous Metastatic Breast Cancer
- Recurrent Basal Cell Carcinoma Nevus Syndrome
- Hemodialysis Arteriovenous (AV) Access
View Our Pipeline
Current Clinical Trials
We are currently conducting clinical trials for our "first-in-class" small-molecule DNA-targeting agent, VAL-083. Because the mechanism of action for VAL-083 is unique, we offer new hope for patients where other treatments may not be effective.
View Our Ongoing Clinical Trials